Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL
Ibrutinib, a Bruton tyrosine kinase inhibitor, provides effective treatment for chronic lymphocytic leukemia (CLL). Here, the authors describe time-dependent molecular changes to malignant cells and to the immune system in patients undergoing ibrutinib therapy, with can be used for therapy monitorin...
Saved in:
Main Authors: | André F. Rendeiro, Thomas Krausgruber, Nikolaus Fortelny, Fangwen Zhao, Thomas Penz, Matthias Farlik, Linda C. Schuster, Amelie Nemc, Szabolcs Tasnády, Marienn Réti, Zoltán Mátrai, Donát Alpár, Csaba Bödör, Christian Schmidl, Christoph Bock |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/73b869eadff94edea5bfbf6a4cfbce75 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
by: Ujjani C, et al.
Published: (2020) -
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
by: Joanne E. Davis, et al.
Published: (2021) -
Single-Cell Sequencing: Biological Insight and Potential Clinical Implications in Pediatric Leukemia
by: Donát Alpár, et al.
Published: (2021) -
Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks
by: André F. Rendeiro, et al.
Published: (2016) -
Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype
by: Thomas Chatzikonstantinou, et al.
Published: (2021)